跳至主要内容
临床试验/NCT07557303
NCT07557303招募中不适用

Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study

Case Western Reserve University3 个研究点 分布在 1 个国家目标入组 1,400 人开始时间: 2026年9月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
1,400
试验地点
3
主要终点
Decision Self-Efficacy

研究概览

简要总结

This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.

The study has one main question:

  • Do participants who use the intervention feel more confident when they make a decision about screening?

Researchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.

What will participants do?

  • Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.
  • Some participants will use the intervention before their first doctor's visit. Other participants will not use it.
  • All participants will talk with a researcher on the phone after their first doctor's visit.
  • Participants who use the intervention will answer a short survey on their phone.
  • A few participants who use the intervention will talk with a researcher a second time on the phone.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.
  • •18 years of age and older
  • •Able to read, speak, and understand English or Spanish
  • •Has not previously been offered prenatal genetic screening for the current pregnancy
  • •24 weeks (6 months) gestational age or less

排除标准

  • •Not pregnant, not a patient at a partner clinical site
  • •Younger than 18 years of age
  • •Not being able to read, speak, and understand English or Spanish
  • •Has previously been offered prenatal genetic screening for the current pregnancy
  • •Greater than 24 weeks gestational age (6 months)

研究组 & 干预措施

Mobile-based Educational Intervention

Experimental

Participants in the intervention arm will access a mobile-based educational tool that provides concise, culturally appropriate information about prenatal genetic screening prior to their clinical visit. Immediately after viewing the intervention, participants will complete an online, 6-question acceptability survey. Participants will then complete a one-time structured quantitative telephone interview within one hundred sixty-eight hours (seven days) of their clinician visit to assess their experience with the intervention and to measure decisional self-efficacy. A select subset of participants will participate in an additional qualitative telephone interview to assess the efficacy and usability of the intervention.

干预措施: Mobile-based Educational Intervention (Behavioral)

Standard of Care

No Intervention

Participants in the standard-of-care arm will receive routine clinical care, including the usual information and counseling provided by clinicians regarding prenatal genetic screening. Participants will complete a one-time structured quantitative telephone interview within one hundred sixty-eight hours (seven days) of their clinician visit to assess their experience being offered prenatal genetic screening and measure decisional self-efficacy.

结局指标

主要结局

Decision Self-Efficacy

时间窗: The scale is completed up to 168-hours (7 calendar days) post-prenatal screening visit.

Decision self-efficacy is measured using a slightly adapted version of the "Decision Self-Efficacy Scale" developed by A. O'Connor and colleagues at the Ottawa Hospital Research Institute and is available at https://decisionaid.ohri.ca. The scale contains eleven questions about a patient's decision-making process. The scale was adapted to ask questions about the context of prenatal genetic screening and utilizes a three-point response scale. Response choices and corresponding point values are: "A lot confident (4), a little confident (2), and not confident (0)". The values from each response are summed, divided by 11 and multiplied by 100 to give a score range from 0 to 100. Zero indicates no confidence and 100 indicates extreme confidence. A researcher administers the scale over the phone, once to each participant, within 168-hours after the medical appointment where participants are offered prenatal genetic screening. It should take no more than 5-10 minutes to complete.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marsha Michie

Associate Director, Department of Bioethics, Bioethics Center for Community Health ANd Genomic Equity (CHANGE), School of Medicine

Case Western Reserve University

研究点 (3)

Loading locations...

相似试验

尚未招募
Phase 3 4
To see how well an awareness program helps people in rural areas understand genetic screening.Obstetrics,
CTRI/2025/03/082165Datta Meghe Institute of Higher Education and Research130
Unknown
不适用
多种类型遗传疾病同步式无创产前筛查的示范应用和推广染色体和单基因疾病
ChiCTR2400083583生殖健康及重大出生缺陷防控研究
已完成
1 期
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.Chronic Inducible Urticaria
2023-504800-28-00Escient Pharmaceuticals Inc.14
尚未招募
2 期
HDCD-092330 tablet for uncomplicated cystitisAcute cystitis, (2) ICD-10 Condition: B998||Other infectious disease,
CTRI/2025/02/081387Himalaya Wellness Company120
已完成
1 期
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.Part C: advanced or unresectable STs (Spain only)Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3)Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)
2023-509969-20-00Celgene Corp.127